Alaska Permanent Fund Corp Biogen Inc. Transaction History

Alaska Permanent Fund Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	BUY	$222.59 - $267.94 $1.36 Million - $1.64 Million	6,103 New	6,103 $1.58 Million
Q4 2022 Feb 08, 2023	SELL	$252.44 - $306.72 $1.75 Million - $2.12 Million	-6,919 Reduced 45.89%	8,160 $2.26 Million
Q3 2022 Oct 31, 2022	BUY	$194.69 - $268.46 $852,547 - $1.18 Million	4,379 Added 40.93%	15,079 $4.03 Million
Q2 2022 Aug 09, 2022	BUY	$187.54 - $223.02 $2.01 Million - $2.39 Million	10,700 New	10,700 $2.18 Million
Q2 2021 Aug 10, 2021	SELL	$259.0 - $414.71 $2.12 Million - $3.4 Million	-8,200 Closed	0 $0
Q3 2020 Oct 29, 2020	BUY	$264.77 - $305.71 $1.26 Million - $1.46 Million	4,760 Added 138.37%	8,200 $2.33 Million
Q1 2020 May 05, 2020	BUY	$268.85 - $341.04 $924,844 - $1.17 Million	3,440 New	3,440 $1.09 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Alaska Permanent Fund Corp, based on Form 13F filings with the SEC.

Stay updated on Alaska Permanent Fund Corp with notifications on news.